Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) reported Q2 EPS of ($0.48), $0.10 worse than the analyst estimate of ($0.38). Revenue for the quarter came in at $102.7 million versus the consensus estimate of $95.68 million.

For earnings history and earnings-related data on Tarsus Pharmaceuticals, Inc. (TARS) click here.